compound semaglutide fda shortage restricts non-approved compounded GLP-1 weight loss products FDA ends semaglutide shortage, closing

Long-term vitamin strategy: beyond the first year GLP-1 therapy is increasingly a long-term proposition

Research Status Research on BPC-157 is currently at an advanced preclinical stage, with a scientific literature comprising more than 100 peer-reviewed publications

Over a one-year treatment period, exercise combined with medication produced 3.9% greater reduction in body fat percentage compared to medication only, while those exercising lost proportionally less muscle mass

F1000Res 2019

Companies in large-population indications (cardiovascular, diabetes, oncology) with small-molecule pipelines face the highest IRA discount to future commercial value

Waldron et al